Summary

Persistence Market Research has recently released a comprehensive report on the worldwide market for non-injectable insulin. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global non-injectable insulin market from 2025 to 2032.

Key Insights:

• Non-injectable Insulin Market Size (2025E): US$1.3 Bn
• Projected Market Value (2032F): US$2.2 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 8.6%

Non-injectable Insulin Market - Report Scope:

Non-injectable insulin refers to alternative insulin delivery formats designed to improve patient compliance and comfort compared to traditional insulin injections. These formulations include oral insulin tablets, inhalable insulin sprays, and other novel delivery systems aimed at enhancing glucose management for patients with diabetes. The market serves patients with Type 1 and Type 2 diabetes across hospitals, specialty clinics, retail pharmacies, and online distribution channels. Growing focus on painless drug delivery, improved adherence, and technological advancements in drug formulation are driving innovation in this segment.

Market Growth Drivers:

The global non-injectable insulin market is primarily driven by the rising prevalence of diabetes worldwide and increasing demand for patient-friendly insulin administration methods. Growing awareness regarding the psychological burden of insulin injections has accelerated interest in alternative delivery systems such as oral and inhaled insulin. Technological advancements in drug encapsulation, pulmonary delivery systems, and peptide stabilization have significantly improved bioavailability and clinical effectiveness. Additionally, expanding healthcare access and rising adoption of digital health and telemedicine platforms are supporting market expansion.

Market Restraints:

Despite strong growth potential, the market faces challenges related to regulatory complexity and stringent clinical approval requirements for novel insulin delivery systems. Ensuring consistent bioavailability and therapeutic equivalence compared to injectable insulin remains a major scientific hurdle. High R&D costs and long development timelines also limit the entry of smaller players. Furthermore, reimbursement uncertainty and limited awareness among healthcare providers in certain regions may slow adoption rates.

Market Opportunities:

The non-injectable insulin market presents substantial opportunities driven by ongoing innovation in oral biologics and pulmonary drug delivery technologies. Increasing investment in diabetes management solutions and rising demand for needle-free treatment options are expected to accelerate commercialization of new products. Strategic collaborations between pharmaceutical companies and biotech firms are fostering pipeline development. Moreover, expanding healthcare infrastructure in emerging economies and growing adoption of personalized medicine approaches offer significant long-term growth potential.

Key Questions Answered in the Report:

• What are the key factors driving the growth of the non-injectable insulin market globally?
• Which product formats (pills, sprays, etc.) are gaining the most traction?
• How are technological advancements improving insulin delivery systems?
• Who are the leading pharmaceutical companies in this space and what strategies are they using?
• What are the major regulatory and clinical challenges affecting market adoption?

Competitive Intelligence and Business Strategy:

Leading players in the global non-injectable insulin market—including Novo Nordisk, Sanofi, and Eli Lilly—are actively investing in next-generation insulin delivery technologies, including oral and inhalable formulations. Companies such as MannKind Corporation and Oramed Pharmaceuticals are focusing on pulmonary and oral insulin platforms, respectively, to differentiate their pipelines. Strategic partnerships, clinical trials, and regulatory engagement remain central to competitive strategy, alongside efforts to improve patient adherence and expand global market reach.

Key Companies Profiled:

• Novo Nordisk
• Sanofi
• Eli Lilly
• MannKind Corporation
• Biocon
• Janssen Pharmaceuticals
• Adocia
• Oramed Pharmaceuticals
• Dance Biopharm
• Medtronic
• Others

Non-injectable Insulin Market Research Segmentation:

By Product Type:

• Pills
• Sprays
• Others

By Distribution Channel:

• Hospital Pharmacies
• Online Stores
• Drug Stores
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Non-injectable Insulin Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. COVID-19 Impact Analysis
2.4. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Value Chain Analysis
3.2. Key Market Players
3.3. Regulatory Landscape
3.4. PESTLE Analysis
3.5. Porter’s Five Force Analysis
3.6. Consumer Behavior Analysis
4. Price Trend Analysis, 2019 - 2032
4.1. Key Factors Impacting Product Prices
4.2. Pricing Analysis, By Product Type
4.3. Regional Prices and Product Preferences
5. Global Non-injectable Insulin Market Outlook
5.1. Market Size (US$ Bn) Analysis and Forecast
5.1.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
5.1.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
5.2. Global Non-injectable Insulin Market Outlook: Product Type
5.2.1. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
5.2.2. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
5.2.2.1. Pills
5.2.2.2. Sprays
5.2.2.3. Others
5.2.3. Market Attractiveness Analysis: Product Type
5.3. Global Non-injectable Insulin Market Outlook: Distribution Channel
5.3.1. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
5.3.2. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
5.3.2.1. Hospitals Pharmacies
5.3.2.2. Online Stores
5.3.2.3. Drug Stores
5.3.2.4. Others
5.3.3. Market Attractiveness Analysis: Distribution Channel
6. Global Non-injectable Insulin Market Outlook: Region
6.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
6.2. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
6.2.1. North America
6.2.2. Latin America
6.2.3. Europe
6.2.4. East Asia
6.2.5. South Asia and Oceania
6.2.6. Middle East & Africa
6.3. Market Attractiveness Analysis: Region
7. North America Non-injectable Insulin Market Outlook
7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.1.1. By Country
7.1.2. By Product Type
7.1.3. By Distribution Channel
7.2. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
7.3.1. Pills
7.3.2. Sprays
7.3.3. Others
7.4. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
7.4.1. Hospitals Pharmacies
7.4.2. Online Stores
7.4.3. Drug Stores
7.4.4. Others
7.5. Market Attractiveness Analysis
8. Europe Non-injectable Insulin Market Outlook
8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.1.1. By Country
8.1.2. By Product Type
8.1.3. By Distribution Channel
8.2. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.2.1. Germany
8.2.2. France
8.2.3. U.K.
8.2.4. Italy
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
8.3.1. Pills
8.3.2. Sprays
8.3.3. Others
8.4. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
8.4.1. Hospitals Pharmacies
8.4.2. Online Stores
8.4.3. Drug Stores
8.4.4. Others
8.5. Market Attractiveness Analysis
9. East Asia Non-injectable Insulin Market Outlook
9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.1.1. By Country
9.1.2. By Product Type
9.1.3. By Distribution Channel
9.2. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.3. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
9.3.1. Pills
9.3.2. Sprays
9.3.3. Others
9.4. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
9.4.1. Hospitals Pharmacies
9.4.2. Online Stores
9.4.3. Drug Stores
9.4.4. Others
9.5. Market Attractiveness Analysis
10. South Asia & Oceania Non-injectable Insulin Market Outlook
10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.1.1. By Country
10.1.2. By Product Type
10.1.3. By Distribution Channel
10.2. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.2.1. India
10.2.2. Indonesia
10.2.3. Thailand
10.2.4. Singapore
10.2.5. ANZ
10.2.6. Rest of South Asia & Oceania
10.3. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
10.3.1. Pills
10.3.2. Sprays
10.3.3. Others
10.4. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
10.4.1. Hospitals Pharmacies
10.4.2. Online Stores
10.4.3. Drug Stores
10.4.4. Others
10.5. Market Attractiveness Analysis
11. Latin America Non-injectable Insulin Market Outlook
11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.1.1. By Country
11.1.2. By Product Type
11.1.3. By Distribution Channel
11.2. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.2.1. Brazil
11.2.2. Mexico
11.2.3. Rest of Latin America
11.3. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
11.3.1. Pills
11.3.2. Sprays
11.3.3. Others
11.4. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
11.4.1. Hospitals Pharmacies
11.4.2. Online Stores
11.4.3. Drug Stores
11.4.4. Others
11.5. Market Attractiveness Analysis
12. Middle East & Africa Non-injectable Insulin Market Outlook
12.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
12.1.1. By Country
12.1.2. By Product Type
12.1.3. By Distribution Channel
12.2. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
12.2.1. GCC Countries
12.2.2. Egypt
12.2.3. South Africa
12.2.4. Northern Africa
12.2.5. Rest of Middle East & Africa
12.3. Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
12.3.1. Pills
12.3.2. Sprays
12.3.3. Others
12.4. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
12.4.1. Hospitals Pharmacies
12.4.2. Online Stores
12.4.3. Drug Stores
12.4.4. Others
12.5. Market Attractiveness Analysis
13. Competition Landscape
13.1. Market Share Analysis, 2024
13.2. Market Structure
13.2.1. Competition Intensity Mapping By Market
13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
13.3.1. Novo Nordisk
13.3.1.1. Overview
13.3.1.2. Segments and Product Type
13.3.1.3. Key Financials
13.3.1.4. Market Developments
13.3.1.5. Market Strategy
13.3.2. Sanofi
13.3.3. Eli Lilly
13.3.4. MannKind Corporation
13.3.5. Biocon
13.3.6. Janssen Pharmaceuticals
13.3.7. Adocia
13.3.8. Oramed Pharmaceuticals
13.3.9. Dance Biopharm
13.3.10. Medtronic
13.3.11. Others
14. Appendix
14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations